The total number of records retrieved from this search are 91. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1246	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationYes	Virus aloneNo	Virus in combination with drug/radiationVSV in combination with cisplatin (0.1 microgram/ml)	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineRichard wong lab	Origin of cell linesquamous cell carcinoma cell line	Cell lineSCCVII	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18043494
IDOV_1247	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationYes	Virus aloneNo	Virus in combination with drug/radiationVSV in combination with cisplatin (0.1 microgram/ml)	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineRichard wong lab	Origin of cell linesquamous cell carcinoma cell line	Cell lineSCCVII	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result80% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18043494
IDOV_1248	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationYes	Virus aloneNo	Virus in combination with drug/radiationVSV in combination with cisplatin (0.1 microgram/ml)	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineRichard wong lab	Origin of cell linesquamous cell carcinoma cell line	Cell lineSCCVII	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18043494
IDOV_1249	Virus nameVesicular stomatitis virus	Virus strainFusogenic strain	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationYes , expressing fusion protein	Virus aloneNo	Virus in combination with drug/radiationVSV in combination with cisplatin (0.1 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineRichard wong lab	Origin of cell linesquamous cell carcinoma cell line	Cell lineSCCVII	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result10% cancer cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18043494
IDOV_1250	Virus nameVesicular stomatitis virus	Virus strainFusogenic strain	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationYes , expressing fusion protein	Virus aloneNo	Virus in combination with drug/radiationVSV in combination with cisplatin (0.1 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineRichard wong lab	Origin of cell linesquamous cell carcinoma cell line	Cell lineSCCVII	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18043494
IDOV_1251	Virus nameVesicular stomatitis virus	Virus strainFusogenic strain	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationYes , expressing fusion protein	Virus aloneNo	Virus in combination with drug/radiationVSV in combination with cisplatin (0.1 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineRichard wong lab	Origin of cell linesquamous cell carcinoma cell line	Cell lineSCCVII	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18043494
IDOV_1599	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyHantaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman Science Research Resource Bank, Japan	Origin of cell lineOral squamous cell line	Cell lineSCC-4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration0.01 MOI	In-vitro result60% cell are viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID19638980
IDOV_1612	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyHantaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman Science Research Resource Bank, Japan	Origin of cell lineOral squamous cell line	Cell lineSCC-4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration0.01 MOI	In-vitro result45% cells are viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID19638980
IDOV_1625	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyHantaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman Science Research Resource Bank, Japan	Origin of cell lineOral squamous cell line	Cell lineSCC-4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration1 MOI	In-vitro result35% cells are viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID19638980
IDOV_1638	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyHantaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHuman Science Research Resource Bank, Japan	Origin of cell lineOral squamous cell line	Cell lineSCC-4	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayLuminiscence measurement	In-vitro virus concentration20 MOI	In-vitro result2% dells are viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID19638980
IDOV_2427	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2428	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2429	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2430	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result50% cell killing after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2431	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.01 MOI	In-vitro result60% cell killing after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2467	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2468	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result90% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2469	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result50% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2470	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result40% cell survival after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2471	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration0.10 MOI	In-vitro result30% cell survival after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2504	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result50% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2505	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2506	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2507	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 7	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2508	Virus nameVaccinia virus	Virus strainGLV-1h151	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeteltion of TK gene and addition of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman squamous cell line	Cell lineSCC-25	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayLDH release and spectrophometer	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22258815
IDOV_2977	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and squamous carcinoma cell line	Cell lineSCC-9	Concentration of cell line7.68E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration2.4 × 10⁸ pfu	In-vitro result33.2 +/- 9.9% cell viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID25890191
IDOV_2978	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and squamous carcinoma cell line	Cell lineSCC-25	Concentration of cell line7.68E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration2.4 × 10⁸ pfu	In-vitro result54.6 +/- 21.5% cell viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID25890191
IDOV_2979	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and squamous carcinoma cell line	Cell lineUM-SCC-38	Concentration of cell line7.68E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration2.4 × 10⁸ pfu	In-vitro result83.9 +/- 16.3% cell viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID25890191
IDOV_2980	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and squamous carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell line7.68E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration2.4 × 10⁸ pfu	In-vitro result97.2 +/- 4.7% cell viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID25890191
IDOV_2981	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and squamous carcinoma cell line	Cell lineUM-SCC-104	Concentration of cell line7.68E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration2.4 × 10⁸ pfu	In-vitro result82.3 +/- 6.5% cell viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID25890191
IDOV_4483	Virus nameHerpes simplex virus	Virus strainRH2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma 34.5 gene and gB gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine squamous cell carcinoma	Cell lineSCCVII	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell survival after 12 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectIncreased extracellular ATP and HMGB1, indicating immunogenic cell death	Clinical trialNA	PMID26987291
IDOV_4484	Virus nameHerpes simplex virus	Virus strainRH2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma 34.5 gene and gB gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine squamous cell carcinoma	Cell lineSCCVII	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell survival after 12 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectIncreased extracellular ATP and HMGB1, indicating immunogenic cell death	Clinical trialNA	PMID26987291
IDOV_4485	Virus nameHerpes simplex virus	Virus strainRH2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma 34.5 gene and gB gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine squamous cell carcinoma	Cell lineSCCVII	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cell survival after 12 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectIncreased extracellular ATP and HMGB1, indicating immunogenic cell death	Clinical trialNA	PMID26987291
IDOV_4486	Virus nameHerpes simplex virus	Virus strainRH2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma 34.5 gene and gB gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine squamous cell carcinoma	Cell lineSCCVII	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result50% cell survival after 12 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectIncreased extracellular ATP and HMGB1, indicating immunogenic cell death	Clinical trialNA	PMID26987291
IDOV_4487	Virus nameHerpes simplex virus	Virus strainRH2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma 34.5 gene and gB gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine squamous cell carcinoma	Cell lineSCCVII	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result40% cell survival after 12 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectIncreased extracellular ATP and HMGB1, indicating immunogenic cell death	Clinical trialNA	PMID26987291
IDOV_4488	Virus nameHerpes simplex virus	Virus strainRH2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma 34.5 gene and gB gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineMurine squamous cell carcinoma	Cell lineSCCVII	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result30% cell survival after 12 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induced apoptosis	Immunogenic effectIncreased extracellular ATP and HMGB1, indicating immunogenic cell death	Clinical trialNA	PMID26987291
IDOV_4619	Virus nameAdenovirus	Virus strainAd5/3-CB016	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 VP per cell	In-vitro result100% cell viablity after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4620	Virus nameAdenovirus	Virus strainAd5/3-CB016	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 VP per cell	In-vitro result100% cell viablity after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4621	Virus nameAdenovirus	Virus strainAd5/3-CB016	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 VP per cell	In-vitro result100% cell viablity after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4622	Virus nameAdenovirus	Virus strainAd5/3-delata 24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 and delta 24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 VP per cell	In-vitro result100% cell viablity after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4623	Virus nameAdenovirus	Virus strainAd5/3-delata 24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 and delta 24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 VP per cell	In-vitro result100% cell viablity after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4624	Virus nameAdenovirus	Virus strainAd5/3-delata 24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 and delta 24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 VP per cell	In-vitro result40% cell viablity after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4625	Virus nameAdenovirus	Virus strainAd5/3-CB016	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 VP per cell	In-vitro result80% cell viablity after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4626	Virus nameAdenovirus	Virus strainAd5/3-CB016	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 VP per cell	In-vitro result80% cell viablity after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4627	Virus nameAdenovirus	Virus strainAd5/3-CB016	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 VP per cell	In-vitro result70% cell viablity after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4628	Virus nameAdenovirus	Virus strainAd5/3-delata 24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 and delta 24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 VP per cell	In-vitro result100% cell killing after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4629	Virus nameAdenovirus	Virus strainAd5/3-delata 24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 and delta 24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 VP per cell	In-vitro result100% cell killing after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4630	Virus nameAdenovirus	Virus strainAd5/3-delata 24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationMutation in delta E3 and delta 24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineUniversity of pitsburgh	Origin of cell lineHuman neck and squamous cell carcinoma cell line	Cell lineUPCI SCC 090	Concentration of cell line3000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 VP per cell	In-vitro result100% cell killing after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27086483
IDOV_4663	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.001 MOI	In-vitro result82% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4664	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.005 MOI	In-vitro result60% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4665	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.01 MOI	In-vitro result55% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4666	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.05 MOI	In-vitro result40% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4667	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.1 MOI	In-vitro result38% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4668	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.5 MOI	In-vitro result38% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4669	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4670	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4671	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.005 MOI	In-vitro result95% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4672	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.01 MOI	In-vitro result90% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4673	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.05 MOI	In-vitro result40% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4674	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.1 MOI	In-vitro result25% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4675	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.5 MOI	In-vitro result22% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4676	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUD-SCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4677	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-74A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.001 MOI	In-vitro result90% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4678	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-74A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.005 MOI	In-vitro result70% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4679	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-74A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.01 MOI	In-vitro result65% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4680	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-74A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.05 MOI	In-vitro result50% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4681	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-74A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4682	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-74A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.5 MOI	In-vitro result38% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4683	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-74A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration1 MOI	In-vitro result38% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4684	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.001 MOI	In-vitro result90% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4685	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.005 MOI	In-vitro result82% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4686	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.01 MOI	In-vitro result60% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4687	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.05 MOI	In-vitro result60% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4688	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4689	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.5 MOI	In-vitro result40% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4690	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration1 MOI	In-vitro result38% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4691	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-11A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.001 MOI	In-vitro result90% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4692	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-11A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.005 MOI	In-vitro result82% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4693	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-11A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.01 MOI	In-vitro result76% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4694	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-11A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.05 MOI	In-vitro result62% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4695	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-11A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.1 MOI	In-vitro result62% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4696	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-11A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.5 MOI	In-vitro result50% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4697	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-11A	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4699	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneNo	Virus in combination with drug/radiationVirus combination with ATN-224 (8 micromolar/litre) an copper chelator show synergy	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineSCC-74A	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.5 MOI	In-vitro result38% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4701	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneNo	Virus in combination with drug/radiationVirus combination with ATN-224 (8 micromolar/litre) an copper chelator show synergy	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineSCC-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.5 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4702	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneNo	Virus in combination with drug/radiationVirus combination with ATN-224 (8 micromolar/litre) an copper chelator show synergy	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineSCC-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.5 MOI	In-vitro result45% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4703	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneNo	Virus in combination with drug/radiationVirus combination with ATN-224 (8 micromolar/litre) an copper chelator show synergy	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineSCC-11A	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.5 MOI	In-vitro result38% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_5906	Virus nameNewcastle disease virus	Virus strainNDV-B1	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and head carcinoma cell line	Cell lineSCC	Concentration of cell line5E+5 pfu	In-vitro toxicityNA	AssayLDH release assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell killing after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced IFN-gamma production	Clinical trialNA	PMIDUS10035984
IDOV_5907	Virus nameNewcastle disease virus	Virus strainNDV-B1	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and head carcinoma cell line	Cell lineSCC	Concentration of cell line5E+5 pfu	In-vitro toxicityNA	AssayLDH release assay	In-vitro virus concentration0.1 MOI	In-vitro resultNo cell death observed after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced IFN-gamma production	Clinical trialNA	PMIDUS10035984
IDOV_5908	Virus nameNewcastle disease virus	Virus strainNDV-F3aa	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationVirus expressing NS1 protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and head carcinoma cell line	Cell lineSCC	Concentration of cell line5E+5 pfu	In-vitro toxicityNA	AssayLDH release assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell killing observed after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced IFN-gamma production	Clinical trialNA	PMIDUS10035984
IDOV_5909	Virus nameNewcastle disease virus	Virus strainNDV-F3aa	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationVirus expressing NS1 protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and head carcinoma cell line	Cell lineSCC	Concentration of cell line5E+5 pfu	In-vitro toxicityNA	AssayLDH release assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell killing after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced IFN-gamma production	Clinical trialNA	PMIDUS10035984